Merck (NYSE: MRK)
Merck Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Merck Company Info
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
News & Analysis
Investing in Cancer Stocks
Learn about some of the leading cancer stocks in the U.S stock market this year.
Why Merck Stock Slipped Today
A change in full-year guidance by management wasn't particularly welcome.
Merck Posts Q2 EPS Beat Revenue Slips
3 Surprisingly Underrated Stocks to Buy Right Now
These big pharma stocks arguably aren't receiving the respect they deserve.
Does This Move Make Merck Stock a Buy?
Got $200? 2 Dividend Stocks to Buy and Hold Forever
Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business
The Largest Healthcare Companies by Market Cap in July 2025
Eli Lilly, Johnson & Johnson, and AbbVie command the healthcare sector.
Valuation
Podcast Episodes
News! News! News! Here's What's Happened in Healthcare Last Week
From a big-time patent settlement between Merck & Co. and Bristol-Myers Squibb, to Johnson & Johnson's earnings, to Aetna and Humana's $37 billion merger bust, we dive into the details behind last week's biggest healthcare stories.
Patent Palooza: One Patent Battle in Hep C, And Another Patent Brawl Brewing On Capitol Hill
Merck, Gilead Sciences, and Ionis get a verdict in their patent suit, and Congress calls for a patent review of Medivation's Xtandi.
Earnings Transcripts
Merck (MRK) Q2 2025 Earnings Call Transcript
None
Merck (MRK) Q4 2024 Earnings Call Transcript
MRK earnings call for the period ending December 31, 2024.
Merck (MRK) Q3 2024 Earnings Call Transcript
MRK earnings call for the period ending September 30, 2024.
Merck (MRK) Q2 2024 Earnings Call Transcript
MRK earnings call for the period ending June 30, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.